tm logo
AKOUOS
Live/Registered
REGISTERED

on 12 Mar 2024

Last Applicant/ Owned by

645 Summer Street, Suite 200

Boston

MA

02210

Serial Number

90332952 filed on 20th Nov 2020

Registration Number

7327850 registered on 12th Mar 2024

in the Principal Register

Correspondent Address

Bruce W. Longbottom

Lilly Corporate Center

Indianapolis, IN 42685

Filing Basis

1. intent to use

2. use application currently

Disclaimer

NO DATA

AKOUOS

The wording "Akouos" has no meaning in a foreign language. Drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; biologics and small molecules both in the nature of pharmaceutical preparations for the treatment of genetically-related inner ear diseases and conditions causing hearing loss; gene therapy products to restore, improve and preserve heRead More

Classification Information


Class [005]
Pharmaceutical Products


Drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; biologics and small molecules both in the nature of pharmaceutical preparations for the treatment of genetically-related inner ear diseases and conditions causing hearing loss; gene therapy products to restore, improve and preserve hearing, namely, genetically engineered tissues for inner ear transplant purposes and drug delivery agents for use in the inner ear consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; gene therapy products, namely, biological preparations for the treatment of inner ear disorders and conditions; viral vectors, non-viral vectors and gene therapy vectors all for medical purposes, namely, therapeutic agents for delivering nucleic acid and other genetic material to nuclei of targeted cells in the human body, for use in gene therapy to treat inner ear disorders and conditions; biotechnological platform technology for gene delivery to biological cells, namely, biological nanoparticles and adenoviruses featuring adeno-associated viral (AAV) vectors therein to provide platforms for specific expressions of biologics with therapeutic effects in gene therapy, all to restore, improve and preserve hearing; biotechnological platform technology for gene delivery to biological cells, namely, biological nanoparticles and adenoviruses featuring adeno-associated viral (AAV) vectors therein to provide platforms for specific expressions of biologics with therapeutic effects in gene therapy, all to treat inner ear disorders and conditions


First Use Date in General

22nd Nov 2023

First Use Date in Commerce

22nd Nov 2023

Mark Details


Serial Number

No 90332952

Mark Type

No Service/Collective Mark

Attorney Docket Number

No

44D Filed

No

44D Current

No

44E filed

No

44E Current

No

66A Filed

No

66A Current

No

Current Basis

No

No Basis

No

Legal History


Show more

Status DateAction Taken
12th Mar 2024REGISTERED-PRINCIPAL REGISTER
12th Mar 2024NOTICE OF REGISTRATION CONFIRMATION EMAILED
03rd Feb 2024NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
02th Feb 2024ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
01st Feb 2024CASE ASSIGNED TO INTENT TO USE PARALEGAL
01st Feb 2024STATEMENT OF USE PROCESSING COMPLETE
11th Jan 2024TEAS STATEMENT OF USE RECEIVED
11th Jan 2024USE AMENDMENT FILED
13th Sep 2023TEAS CHANGE OF OWNER ADDRESS RECEIVED
13th Sep 2023APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED